Special Issues

Special Issue Title: Advances in multiple sclerosis research

· Print Special Issue Flyer

· Deadline for manuscript submissions: 20 June 2021

Special Issue Editor

Guest Editor

Dr. Samar S. Ayache 

EA 4391, Excitabilité Nerveuse et Thérapeutique, Faculté de Médecine, Université Paris-Est, Créteil, France 

Website | E-Mail

Interests: Multiple sclerosis, tDCS, TMS, cortical excitability, cartography

 Dr. Moussa A. Chalah 

 EA 4391, Excitabilité Nerveuse et Thérapeutique, Faculté de Médecine, Université Paris-Est, Créteil, France

Website | E-Mail

Interests: Multiple sclerosis, cortical excitability, TMS, tDCS

Special Issue Information

Dear Colleagues,

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system and is one of the most common causes of disability in young adults. From a pathological perspective a triad of inflammation, demyelination and neurodegeneration characterizes this disease. MS patients can suffer from a plethora of symptoms, among which stand the sensorimotor, cerebellar, emotional and cognitive manifestations. The last decade has witnessed an impressive pharmacological development that has offered more efficient therapeutic strategies that the ones available in the last century. Despite these advances, several symptoms remain unnoticed, are poorly assessed and lack adequate treatment. In this context fatigue, pain, sleep disorders, emotional disturbances and cognitive manifestations could be perceived as “silent symptoms” that could seriously alter the quality of life of MS patients and are usually overlooked in this population.

Therefore, research is highly needed in order to properly address the pathophysiology of these symptoms, propose new screening tools and most importantly assess innovative therapeutic interventions.

The aim of this Research Topic is to shed light on the utility of innovative approaches in MS. This concerns original research that applies clinical, molecular, cellular, or neuroimaging approaches to unravel the underlying mechanisms of MS-related symptoms. In addition, testing new pharmacological agents or alternative interventions in this context would be of great interest. Review articles that analyze the current literature on the above-mentioned topics are welcomed. Case reports also fall within the scope of this subject. Research involving animal models of MS would also be considered.

Furthermore, works that aim to explore the brain physiology in this disease allows a better understanding of the underlying mechanisms of MS related symptoms, and would pave the way to the development of objective tools to monitor their clinical evolution and therapeutic responses.

Dr. Samar S. Ayache and Dr. Moussa Chalah

Guest Editor


Manuscript Submission Information

Manuscripts should be submitted online at https://jour.ipublishment.com/imr/access/login by registering and logging into this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Integrative Neuroscience is an international peer-reviewed open access quarterly journal published by IMR Press.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is $1500. We normally offer a discount greater than 30% (APC: $1050) to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial board member. Submitted papers should be well formatted and use good English.


Multiple sclerosis, assessment, interventions, pathophysiology, therapies

Share This Special Issue


Published Papers (2 papers)
Please wait a minute...
For Selected: Toggle Thumbnails
Vitamin D, Epstein-Barr virus, and endogenous retroviruses in multiple sclerosis - facts and hypotheses
Christine Brütting, Gabriele I. Stangl, Martin S. Staege
Journal of Integrative Neuroscience    2021, 20 (1): 233-238.   DOI: 10.31083/j.jin.2021.01.392
Abstract120)   HTML11)    PDF(pc) (119KB)(153)       Save

The pathogenesis of multiple sclerosis (MS) remains poorly understood. Presumably, MS is caused by multiple environmental, epigenetic, and genetic factors. Among them, human endogenous retroviruses (HERVs), Epstein-Barr virus (EBV) and vitamin D have been suggested to play a role in the pathogenesis and course of MS. Because vitamin D can affect the immune system and infections, it can be hypothesized that there is a close interplay between vitamins, EBV and ERV in the pathogenesis of MS. Here, we summarize the important data on vitamin D, including polymorphisms in genes related to vitamin D metabolism, EBV and ERV, in the pathogenesis of MS and create hypotheses regarding their interactions. Data indicate that vitamin D has a strong impact on viral infections and interferes with EBV infection, while EBV is capable of activating silent ERVs. We believe that EBV could be the missing link between vitamin D and ERV in MS pathogenesis.
Related Articles | Metrics
Computerized cognitive rehabilitation for treatment of cognitive impairment in multiple sclerosis: an explorative study
Irini Vilou, Christos Bakirtzis, Artemios Artemiadis, Panagiotis Ioannidis, Malamati Papadimitriou, Eleni Konstantinopoulou, Eleni Aretouli, Lambros Messinis, Grigorios Nasios, Efthimios Dardiotis, Mary Helen Kosmidis, Nikolaos Grigoriadis
Journal of Integrative Neuroscience    2020, 19 (2): 341-347.   DOI: 10.31083/j.jin.2020.02.35
Abstract469)   HTML20)    PDF(pc) (225KB)(434)       Save
In this explorative study, forty-seven patients with relapsing-remitting multiple sclerosis were randomized to a custom 6-week cognitive rehabilitation intervention (n = 23) using the BrainHQTM web-based platform and to a control group condition (n = 24). Cognitive rehabilitation intervention consisted of two 40-minute sessions per week. All patients were tested with the Brief International Cognitive Assessment for Multiple Sclerosis battery, the Stroop Color-Word Test, and the trail making test, while the Beck Depression Inventory - Fast Screen questionnaire was used as a measure of mood and the cognitive reserve index as a measure of cognitive reserve. We used the reliable change index, to calculate clinically meaningful changes of performance, and to discriminate between responders and non-responders of this intervention. Statistically significant improvement of the group receiving treatment was observed mainly on measures of verbal and non-verbal episodic memory and, to a lesser extent, on reading speed, selective attention/response inhibition, and visual attention. Verbal memory and visual attention improvements remained significant after considering the corrected for multiple comparisons level of significance. According to reliable change index scores, 12/23 (52.2%) of patients in the intervention group presented meaningful improvement in at least one measure (Greek Verbal Learning Test: 26%, Brief Visuospatial Memory Test-Revised: 17.4%, Stroop-Words test: 13%). This explorative study provides evidence that, at least in the short term, cognitive rehabilitation may improve the cognitive performance of multiple sclerosis patients.
Supplementary Material | Related Articles | Metrics

Current Issue

  • Volume 20, Issue 1